Home > Boards > US Listed > Biotechs >

Intellia Therapeutics Inc. (NTLA)

NTLA RSS Feed
Add NTLA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/30/2021 9:59:09 PM - Followers: 13 - Board type: Free - Posts Today: 0

Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.
NTLA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTLA News: Quarterly Report (10-q) 05/06/2021 04:08:42 PM
NTLA News: Intellia's Q1 net loss widens as CRISPR biotech misses earnings expectations 05/06/2021 08:10:52 AM
NTLA News: Current Report Filing (8-k) 05/06/2021 07:46:08 AM
NTLA News: Intellia Therapeutics Q1 2021 Earnings Preview 05/05/2021 12:57:11 PM
NTLA News: Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates 04/29/2021 07:30:00 AM
PostSubject
#18   Adding CD8 coreceptors may enhance CD4+ T-cell responses jondoeuk 04/30/21 09:59:09 PM
#17   Knock-ins, knockdowns and/or overexpression are other ways to jondoeuk 04/30/21 09:50:55 PM
#16   In the setting of established and (rapidly) proliferating jondoeuk 04/30/21 09:43:58 PM
#15   This was presented at SITC last year https://jitc.bmj.com/content/8/Suppl_3/A103 jondoeuk 04/30/21 04:21:06 PM
#14   This trial showed that donor-derived, CD8+ T-cells engineered jondoeuk 04/30/21 04:19:29 PM
#13   https://www.businesswire.com/news/home/20210107005234/en/ArsenalBio-Announces-Mu jondoeuk 01/09/21 05:49:48 PM
#12   Cathie Wood likes some cutting edge Gene editing Fress 01/07/21 10:28:57 AM
#11   NTLA 5001, a T Cell Product Candidate with jondoeuk 12/05/20 01:22:47 PM
#10   Arsenal Bio [1] is also using it for jondoeuk 11/25/20 02:59:16 PM
#9   Currently, the company is using CRISPR/Cas9 screening to jondoeuk 11/25/20 02:58:37 PM
#8   Preclinical data (at ASH) https://ashpublications.org/blood/article/136/Suppleme jondoeuk 11/04/20 06:06:01 PM
#7   Bought more at $18.30 before selling all @ chmcnfunds 01/08/18 01:50:15 PM
#6   CRISPR hits a snag: Our immune systems may chmcnfunds 01/08/18 10:57:51 AM
#5   In at $18.90. Got to believe the drop chmcnfunds 01/08/18 10:56:50 AM
#4   I don't have enough understanding on how the rule_rationale 10/09/17 01:19:13 PM
#3   Am I the only one that thinks this jimski55 10/06/17 03:38:42 PM
#2   Which of the big three is closest to redspinelpinktopaz 03/07/17 02:18:43 PM
#1   Took a starter here, CRISPR could do amazing things! rule_rationale 05/10/16 11:00:34 AM
PostSubject
Consent Preferences